checkAd

     101  0 Kommentare Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence - Seite 3

    Viveve is a registered trademark of Viveve, Inc.

    Investor Relations contacts:
    Amato and Partners, LLC
    Investor Relations Counsel
    admin@amatoandpartners.com

    Media contact:
    Bill Berry
    Berry & Company Public Relations
    (212) 253-8881
    bberry@berrypr.com

    Lesen Sie auch

    SOURCE: Viveve Medical, Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/729574/Viveve-Announces-Issuance-of-Second- ...


    The Viveve Medical Registered (Old) Stock at the time of publication of the news with a fall of -4,08 % to 0,513USD on NYSE stock exchange (02. Dezember 2020, 02:00 Uhr).

    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von Accesswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence - Seite 3 Patent further strengthens Viveve's novel dual-energy technology intellectual property portfolio as company plans for completion of pivotal PURSUIT clinical trialENGLEWOOD, CO / ACCESSWIRE / December 1, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a …